Cannabis Dependence Clinical Trial
Official title:
Quitting Marijuana Use: Self-Report Study of Quitting Strategies and Withdrawal Symptoms
Background:
- Marijuana is the most widely used illicit drug in the world, yet relatively little is known
about users who try to quit without formal treatment ( spontaneous quitting). Studies have
suggested that there are some common strategies that many individuals use in spontaneous
quitting, such as changing one s lifestyle or identity, reminding oneself of negative
consequences, support from family and friends, and religion. However, more research is needed
to determine potential treatment strategies for marijuana use.
Objectives:
- To identify strategies used to help with marijuana quitting among non-treatment seeking
adult marijuana users.
- To identify withdrawal symptoms experienced during marijuana quitting and their
relationship to the quitting strategies used and the outcome of the quit attempt.
- To evaluate whether subgroups of marijuana users differ in their experience of marijuana
quitting.
Eligibility:
- Individuals at least 18 years of age who have made at least one attempt to quit marijuana
use.
Design:
- The study will consist of one visit of approximately 1 to 2 hours.
- Participants will fill out three questionnaires. The questionnaires have different types
of questions, and will ask about background and lifestyle, marijuana use and craving
patterns and behaviors, and difficulties in previous attempts to quit using marijuana.
Marijuana is the most widely used illicit drug in the world, yet relatively little is known about users who try to quit without formal treatment (so-called spontaneous quitting). This study will use two self-report questionnaires to collect information on the socio-demographic characteristics, marijuana use history, most difficult marijuana quit experience, and marijuana craving from a convenience sample of 1230 adult, non-treatment-seeking marijuana users. The questionnaires take 45-60 minutes to administer. Data will be analyzed for patterns and correlations among the characteristics of the quit attempt, including any withdrawal symptoms, quitting strategies used, and its success. The marijuana craving data will be analyzed to evaluate the validity of this measure of marijuana craving. There are no direct benefits to subjects from study participation. The scientific benefit is an improved understanding of spontaneous quitting of marijuana use, which may lead to improved interventions for marijuana users in the future. There are no physical risks to subjects. There are risks of anxiety or embarrassment while taking the questionnaire and of loss of confidentiality of sensitive information collected about subjects. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01005810 -
A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana
|
Phase 2 | |
Completed |
NCT00114439 -
Lithium Cannabis Withdrawal Study
|
Phase 2 | |
Completed |
NCT00350285 -
The Teen Marijuana Check-Up
|
Phase 2 | |
Completed |
NCT01618656 -
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
|
Phase 2 | |
Completed |
NCT01153490 -
Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine
|
Phase 4 | |
Completed |
NCT02946489 -
Facilitating the Behavioral Treatment of Cannabis Use Disorder
|
Phase 1 | |
Completed |
NCT02088177 -
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01565174 -
The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis
|
N/A | |
Completed |
NCT01697709 -
Quetiapine Pharmacotherapy for Cannabis Dependence
|
Phase 2 | |
Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
Completed |
NCT00167297 -
Atomoxetine for the Treatment of Cannabis Dependence
|
Phase 2 | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT01611948 -
Treatment for Cannabis Withdrawal and Dependence
|
Phase 2 | |
Recruiting |
NCT03221231 -
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
|
Phase 4 | |
Not yet recruiting |
NCT03366909 -
Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness
|
N/A | |
Completed |
NCT01639872 -
Clozapine for Cannabis Use in Schizophrenia
|
Phase 4 | |
Not yet recruiting |
NCT06334016 -
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
|
Early Phase 1 | |
Completed |
NCT01793961 -
Effects of Chronic Intake of Cannabis on Contrast Sensitivity
|
N/A | |
Completed |
NCT01834794 -
Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders
|
N/A | |
Completed |
NCT01747850 -
Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence
|
Phase 2 |